The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results.
 
Marina Maglakelidze
No Relationships to Disclose
 
Iurie Bulat
No Relationships to Disclose
 
Dinara Ryspayeva
Honoraria - AstraZeneca
Consulting or Advisory Role - MSD Oncology
Speakers' Bureau - Takeda
Research Funding - Odonate Therapeutics
Travel, Accommodations, Expenses - MSD Oncology
 
Boris Milev Krastev
Consulting or Advisory Role - G1 Therapeutics
Research Funding - G1 Therapeutics
Travel, Accommodations, Expenses - ROCHE, Pfizer
 
Maia Gogiladze
No Relationships to Disclose
 
Adrian Crijanovschi
No Relationships to Disclose
 
Philippe Georges Aftimos
Honoraria - Gilead Sciences; Roche; Synthon
Consulting or Advisory Role - Amcure; Amgen; Boehringer Ingelheim; G1 Therapeutics; Macrogenics; Novartis; Novartis; Radius Health; Roche; Servier
Travel, Accommodations, Expenses - Amgen; MSD Oncology; Pfizer; Roche Belgium
 
Patrick Neven
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Radius Health (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Lilly (Inst); Pfizer (Inst); Roche (Inst)
 
Mark D. Pegram
Honoraria - Genentech/Roche; Pfizer; Seagen
Consulting or Advisory Role - Genentech/Roche; Pfizer; Seagen
 
Catharina Wilhelmina Menke
Research Funding - G1 Therapeutics (Inst); Radius Health (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Elizabeth Claire Dees
Consulting or Advisory Role - G1 Therapeutics; Novartis (I); Strata Oncology
Research Funding - Bayer; Cerulean Pharma; Genentech/Roche; H3 Biomedicine; Lilly; Merck; Meryx Pharmaceuticals; Novartis; Pfizer
Travel, Accommodations, Expenses - G1 Therapeutics
 
Carolien P. Schroder
No Relationships to Disclose
 
A. Jager
No Relationships to Disclose
 
Linnea I. Chap
Consulting or Advisory Role - Biotherapeutics; Seagen
Speakers' Bureau - Genentech; Pfizer
 
Erika P. Hamilton
Consulting or Advisory Role - Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dantari (Inst); Deciphera (Inst); Eisai (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Akeso Biopharma (Inst); Amgen (Inst); ArQule (Inst); Arvinas (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Clovis Oncology (Inst); Compugen (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dana Farber Cancer Hospital (Inst); Deciphera (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Fochon Pharmaceuticals (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); H3 Biomedicine (Inst); Harpoon (Inst); Hutchison MediPharma (Inst); Immunogen (Inst); Immunomedics (Inst); Infinity Pharmaceuticals (Inst); InventisBio (Inst); Karyopharm Therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Lycera (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Molecular Templates (Inst); Novartis (Inst); Nucana (Inst); Olema Pharmaceuticals (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); Orinove (Inst); Pfizer (Inst); PharmaMar (Inst); Plexxikon (Inst); Polyphor (Inst); Puma Biotechnology (Inst); Radius Health (Inst); Regeneron (Inst); Rgenix (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Shattuck Labs (Inst); Silverback Therapeutics (Inst); Stem CentRx (Inst); Sutro Biopharma (Inst); Syndax (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TapImmune Inc. (Inst); Tesaro (Inst); Torque (Inst); Torque (Inst); Verastem (Inst); Zenith Epigenetics (Inst); Zymeworks (Inst)
 
Massimo Cristofanilli
Consulting or Advisory Role - CytoDyn; Foundation Medicine; G1 Therapeutics; Lilly; Sermonix Pharmaceuticals
Speakers' Bureau - Foundation Medicine; Pfizer
Research Funding - CytoDyn (Inst); G1 Therapeutics (Inst); Lilly (Inst); Sermonix Pharmaceuticals (Inst)
 
Susanna Varkey Ulahannan
Consulting or Advisory Role - Array BioPharma; Bayer; Eisai; Exelixis; Incyte; Syros Pharmaceuticals
Research Funding - Abbvie (Inst); ArQule (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CicloMed (Inst); evelo biosciences (Inst); G1 Therapeutics (Inst); Incyte (Inst); Klus Pharma (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); OncoMed (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst)
 
Jorianne Boers
No Relationships to Disclose
 
Ramsha Iqbal
No Relationships to Disclose
 
Sarika Jain
Employment - G1 Therapeutics
Stock and Other Ownership Interests - G1 Therapeutics